A Modern View on the Diagnostic and Therapy Anemia Chronic Diseases Problems

С. А. Гусєва, С. В. Луценко


Anemia is an important disease often found in the elderly. Аnemia of chronic diseases is relatively frequent. Anemia of chronic diseases may result from chronic infectious disease, chronic inflammatory disease. When anemia is found in the elderly, it is important to determine if it is explained by physiological changes or if there is an underlying disease the treatment of which can improve the anemia.


аnemia in the elderly; anemia of chronic diseases; peculiarities of diagnosis and treatment


Price E.A., Schrier S.L. Anemia in the elderly: introduction. Semin Hematol. 2008;45:207–209.

Дубикайтис О.В., Колосков А.В. Анемия у пожилых людей. Гематология 2011,том 12: 886-889

Ania B.J., Suman V.J., Fairbanks V.F., et al. Incidence of anemia in older people: an epidemiologic study in a well defined population. J. Am. Geriatr. Soc. 1997; 45: 825-831.

Schrijvers D., Highley M., De Bruyn E., et al. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Anticancer Drugs 1999; 10: 147-153.

Price EA, Schrier SL. Anemia in the elderly: introduction. Semin Hematol. 2008;45:207–209.

Gabrilove J. Overview: erythropoiesis, anemia, and the impact of erythropoietin. Semin. Hematol. 2000; 37, Suppl. 6: 1-3.

Zauber N.P., Zauber A.G. Hematologic data of healthy very old people. JAMA 1987;257: 2181-2184.

Inelmen E.M., Alessio M.D., Gatto M.A., et al. Descriptive analysis of the prevalence of anemia in a randomly selected sample of elderly people at home: some results of an Italian multicentric study. Aging 1994; 6: 81-89.

Quaglino D., Ginaldi L., Furia N., et al. The effect of age on hemostasis . Aging (Milano)1996; 8: 1-12.

Smith D.L. Anemia in the elderly.Am. Fam. Physician 2000; 62: 1565-1572.

Balducci L. Anemia, cancer and aging. Cancer Control. 2003; 10: 478-486.

Гороховская Г.Н., Завьялова А.И., Петина М.М. Гериатрические аспекты железодефицитных анемий. Русский медицинский журнал 2008;10: 1 – 10.

Patel K.V. Epidemiology of anemia in older adults. Semin. Hematol. 2008;45:210–217.

Masatsugu Ohta. Management of Anemia in the Elderly. JMAJ 52(4): 219–223, 2009.

Goodnough LT, Price TH, Parvin CA. The endogenous erythropoietin response and the erythropoietic response to blood loss anemia: the effects of age and gender. J. Lab. Clin. Med. 1995;126: 57-64.

Nafziger J., Pailla K., Luciani L., et al. Decreased erythropoietin responsiveness to iron deficiency anemia in the elderly. Am. J. Hematol. 1993;43:172-176.

Ania B.J., Suman V.J., Fairbanks V.F., et al. Prevalence of anemia in medical practice: community versus referral patients. Mayo. Clin. Proc. 1994; 69: 730-735.

Krantz S.B. Pathogenesis and treatment of the anemia of chronic disease. Am. J. Med. Sci.1994; 307: 353-359.

Cleeland C.S., Demetri G.D., Glaspy J., et al. Identifying hemoglobin levels for optimal quality of life: results of an incremental analysis. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 1999; 18: 2215.

Эритропоэтин. Биологические свойства и клиническое применение (Под ред. проф. С.А. Гусевой и чл.-кор. АМН Украины проф. В.Г.Бебешко). Киев: Логос, 2005: 422 с.

Ganz T: Anemia of chronic disease. In: Lichtman MA, Beutler E, Kipps TJ, et al. ed. Williams Hematology, 7th ed. New York: McGraw-Hill; 2006: 565–570.

Price E.A., Schrier S.L. Unexplained Aspects of Anemia of Inflammation. Adv. Hematol. 2010; 10: 1– 4.

Means Jr RT. Anemias secondary to chronic disease and systemic disorders. In: Greer JP, Foerster J, Rodgers GM, et al. ed. Wintrobe’s Clinical Hematology 12th ed. Philadelphia: Lippincott Wiliams & Wilkins; 2009:1221–1238.

Tong E.M., Nissenson A.R. Erythropoietin and anemia. Semin. Nephrol. 2001; 21: 190-203.

Zarychanski R., Houston D.S. Anemia of chronic disease: A harmful disorder or an adaptive,beneficial response. CMAJ. 2008; 179: 333-337.

Mazess RB. Biological adaptation: aptitudes and acclimatization. In: Watts ES, Johnston FE,Lasker GW, editors. Biosocial interrelations in population adaptation. The Hague: Mouton; 2008. – P. 9-18.

Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003;101:2461–2463.

Nemeth E., Ganz T. The role of hepcidin in iron metabolism. Acta Haematol. 2009;122: 78–86.

Weinberg ED. Iron depletion: a defense against intracellular infection and neoplasia. Life Sci. 1992;50: 1289-1297.

Afzali B., Goldsmith D.J. Intravenous iron therapy in renal failure: Friend and foe. J.Nephrol. 2004;17: 487-495.

Fleming R.E., Sly W.S. Mechanisms of iron accumulation in hereditary hemochromatosis. Annu Rev Physiol 2002; 64:663–80;

Finch C. Regulators of iron balance in humans. Blood 1994; 84:1697–702.

Krause A., Neitz S., Magert H.J. et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000;480:147–150

Park C.H., Valore E.V., Waring A.J. et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276:7896–910.

Beaumont C. Molecular mechanisms of iron homeostasis. Med Sci (Paris). 2004;20(1):68-72.26

Tussing-Humphreys L., Pusatcioglu C., Nemeth E., Braunschweig C. Rethinking iron regulation and assessment in iron deficiency, anemia of chronic disease, and obesity: introducing hepcidin. J. Acad. Nutr. Diet. 2012; 112(3): 391-400.

Nicolas G., Bennoun M., Porteu A., et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc. Natl. Acad. Sci. U S A. 2002; 99: 4596–4601.

Papanikolaou G, Tzilianos M, Christakis JI., et al. Hepcidin in iron overload disorders. Blood 2005; 105: 4103–4105.

Young B., Zaritsky J. Hepcidin for Clinicians. Clin. J. Am. Soc. Nephrol. 2009; 4: 1384–1387.

Valore E.V., Ganz T. Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin. Blood Cells Mol. Dis. 2008; 40:132–138.

Chung J., Prohaska J.R., Wessling-Resnick M. Ferroportin-1 is not upregulated in copper-deficient mice. J Nutr. 2004; 134 (3): 517 – 521.

Hebert P.C., Van der Linden P., Biro G., et al. Physiologic aspects of anemia. Crit. Care. Clin. 2004; 20: 187-212.

Thomas D. The physiology of oxygen delivery. Vox Sang 2004; 87, Suppl. 1: 70-73.

Ick B.E., Rigolet M., Van Der Linden P.J. Cardiovascular and metabolic response to acute normovolemic anemia. Effects of anesthesia .Anesthesiology 2000; 93: 1011-1016.

Van der Linden P., De Hert S., Mathieu N., et al. Tolerance to acute isovolemic hemodilution. Effect of anesthetic depth. Ibid 2003; 99: 97-104.

Bowens C. Jr., Spahn D.R., Frasco P.E., et al. Hemodilution induces stable changes in global cardiovascular and regional myocardial function. Anesth. Analg. 1993; 76: 1027-1032.

Weiskopf R.B., Viele M.K., Feiner J., et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA 1998; 279: 217-221.

Gledhill N., Warburton D., Jamnik V. Haemoglobin, blood volume, cardiac function, and aerobic power. Can. J. Appl. Physiol. 1999% 24: 54-65.

Ahluwalia N., Lammi-Keefe C.J., Bendel R.B., et al. Iron deficiency and anemia of chronic disease in elderly women: a discriminate-analysis approach for differentiation. Am. J. Clin.Nutr. 1995;61: 590-596.

Glaspy J., Bukowski R., Steinberg D., et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice: Procrit Study Group, J. Clin. Oncol. 1997;15: 1218-1234.

Demetri G.D., Kris M., Wade J., et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J.Clin. Oncol. 1998; 16: 3412-3425.

Littlewood T.J., Bajetta E., Nortier J.W., et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 2001; 19: 2865-2874.

Assessing the iron status of populations: including literature reviews: report of a Joint World Health Organization / Centers for Disease Control and Prevention Technical Consultation on the Assessment of Iron Status at the Population Level. Geneva, Switzerland, 2004: 108 p

Гусева С. А., Гончаров Я. П. Анемии. Киев: Логос, 2010: 408 с.

Cazzola M., Messinger D., Battistel V. et al. Recombinant human erythropoietin in anemia associated with multiple myeloma or non-Hodgkin’ s lymphoma: Dose finding and identification of predictors of response. Blood 1997; 90: 358а.

Volkova N., Arab L. Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients . Am. J. Kidney. Dis. 2006; 47: 24-36.

Lindenfeld J. Prevalence of anemia and effects on mortality in patients with heart failure.Am. Heart. J. 2005; 149: 391-401.

Caro J.J., Salas M., Ward A., et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91:2214-2221.

Bolger A.P., Doehner D., Sharma R. Anaemia in chronic heart failure: the relationship to inflammatory cytokine expression and prognostic importance. Circulation 2002;106:570-571.

Kosiborod M., Curtis J.P., Wang Y., et al. Anemia and outcomes in patients with heart failure: a study from the National Heart Care Project. Arch. Intern. Med. 2005; 165:2237-2244.

Watine J. Prognostic evaluation of primary non-small cell lung carcinoma patients using biological fluid variables. A systematic review. Scand. J. Clin. Lab. Invest. 2000;60:259-273.

Zarychanski R., Houston D.S. Anemia of chronic disease: A harmful disorder or an adaptive,beneficial response. CMAJ 2008; 179: 333-337.

Robson K. J. Hepcidin and its role in iron absorption. Biol. Res. 2006; 39: 95 – 105.

Copyright (c) 2020 С. А. Гусєва, С. В. Луценко

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

ISSN 2412-8708 (Online), ISSN 2307-5112 (Print)

Flag Counter

ISSN (print): 2307-5112.